Trial · NCT06897579
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
NCT06897579, Phase 2, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer. Trials, record NCT06897579. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06897579
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
- NCT number
- NCT06897579
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 40 participants, actual
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule, Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection
- First posted
- 2025-03-27
- Last updated
- 2026-04-28
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) | From enrollment until the first onset of disease progression or death from any cause, evaluation is expected to take 2 years | The time from enrollment until the first onset of disease progression or death from any cause, whichever occurs first. |
| Secondary | 12/24 month PFS rate | 12-month, 24-month | The percentage of subjects with no progression from the first dose to 12 and 24 months of total subjects. |
| Secondary | 12/24 month Overall survival (OS) rate | 12-month, 24-month | The number of surviving subjects as a percentage of the total number of subjects from the first dose to 12 and 24 months. |
| Secondary | Overall survival (OS) | From randomization to death from all causes, evaluation is expected to take 5 years | The time between randomization and death from all causes. |
| Secondary | Objective response rate (ORR) | Complete response time was achieved, evaluation is expected to take 2 years | The proportion of subjects achieving complete response (CR) or partial response (PR) was assessed. |
| Secondary | Disease Control Rate (DCR) | Complete response time was achieved, evaluation is expected to take 2 years | The proportion of subjects who achieved complete response (CR), partial response (PR), or stable disease (SD) was assessed. |
| Secondary | Incidence of adverse events (AE) and serious adverse events (SAE) | Time of adverse event, evaluation is expected to take 2 years | The incidence and severity of adverse events were determined according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 rating scale. |
| Secondary | Patient-reported Outcomes (PRO): Treatment of Cancer Quality of Life Questionnaire - Core 30 | PRO assessments were performed during the screening period, at the end of each even-numbered cycle, at the end of study treatment, and at safety follow-up in the order shown, baseline to 2 years | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30). Treatment of Cancer Quality of Life Questionnaire - Core 30 were used to evaluate PRO. The EORTC QLQ-C30 v3 questionnaire is an established measure of health-related quality of life (HRQoL)Methods, it is often used as the end point of tumor clinical trials.A score of 0-100, where higher scores indicate greater function, higher HRQoL, or higher symptom levels. |
| Secondary | Patient-reported Outcomes (PRO): EORTC QLQ-LC13 | PRO assessments were performed during the screening period, at the end of each even-numbered cycle, at the end of study treatment, and at safety follow-up in the order shown, baseline to 2 years | EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) QLQ-LC13 were used to evaluate PRO.The QLQ-LC13 is a 13-item self-filling questionnaire for lung cancer disease that will be associated with the EORTC Use QLQ-C30 together.4-point scale: "Not at all", "somewhat", "quite a bit" and "to a great extent" |
| Secondary | Patient-reported Outcomes (PRO): European Quality of Life-5 Dimensions 5 Levels | PRO assessments were performed during the screening period, at the end of each even-numbered cycle, at the end of study treatment, and at safety follow-up in the order shown, baseline to 2 years | European Quality of Life-5 Dimensions 5 Levels were used to evaluate PRO. EuroQol- 5 Dimension (EQ-5D) is a standardized health status indicator developed by the EuroQol group, which asseses five dimensions: mobility, self-care, general activity, pain/discomfort, and anxiety/depression.Each dimension has five response options that reflect increased difficulty (no problem, some problem, moderate problem, severe)Serious problem (extremely serious problem). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06897579
GET https://conductscience.org/api/trials/v1/NCT06897579/registered